Zymeworks Deal History & Licensing Activity
Zymeworks is a large biotech headquartered in Canada. Over the past three years, Zymeworks has been involved in 5 licensing and acquisition transactions, with a primary focus on Other (6 deals). The company currently has 4 active clinical trials, primarily in Mega Deals.
Deals (12mo)
3
Active Trials
4
Top Modality
Other
Focus Area
Mega Deals
Zymeworks Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Zymeworks in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| lung disease drug and royalty assets | Theravance | Other | Unknown | acquisition | Jul 11, 2026 |
| lung disease drug + royalty interests | Theravance Biopharma | Other | Unknown | acquisition | Jul 3, 2026 |
| Theravance Biopharma | Theravance Biopharma | Other | Unknown | acquisition |
Zymeworks Pipeline Focus
Therapeutic areas and modalities where Zymeworks is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Zymeworks Strategic Signals
Key indicators of Zymeworks's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Zymeworks Clinical Pipeline
Zymeworks has 4 active clinical trials across 3 development phases.
2
Phase 1
1
Phase 2
1
Phase 3
See How Your Asset Matches Zymeworks's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Zymeworks Licensing & Deal Activity
Zymeworks is a large biotech company based in Canada that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Zymeworks ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Zymeworks include Mega Deals (6 deals and trials), Oncology (2 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, Zymeworks has shown particular interest in other, small molecules, rnai.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Zymeworks and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Zymeworks's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.